GLOW Blend Vials Explained: Co-Lyophilisation, Lab Reports and Storage

LynxLab · 24 October 2026 · 7 min read

How three peptides end up in one freeze-dried vial, how a certificate of analysis reports each one, and what the stability literature says about storage.

Photo: CDC, Unsplash

A single-peptide vial is easy to read: one compound, one purity figure, one mass. A blend like GLOW, which holds BPC-157, TB-500 and GHK-Cu in the same 70mg cake, raises practical questions that the research papers never answer. How do three peptides get into one vial, how does a lab report prove each one is there, and does a mixture keep as well as its parts?

What lyophilisation does to a peptide solution

Lyophilisation is freeze-drying. The FDA's inspection guide on lyophilisation of parenterals describes it as three separate but interdependent processes: freezing, primary drying by sublimation, and secondary drying by desorption. Water leaves the frozen product as vapour without the product ever being heated to a damaging temperature.

The same guide lists why manufacturers bother. A liquid is easy to filter and fill aseptically; a dry powder is far more stable than a solution; and a well-made cake dissolves quickly when the diluent goes back in. The main cost is the need for a sterile diluent at the point of use.

The process steps are standard. The compound and any excipients are dissolved in water for injection, the bulk solution is sterilised by filtration, vials are filled and partially stoppered, then frozen below the eutectic point before the chamber is pumped down to drive sublimation.

Co-lyophilisation: three peptides, one solution, one cake

A co-lyophilised blend follows the same route with one change at the start. Instead of a single peptide, BPC-157, TB-500 and GHK-Cu are weighed, dissolved together in one bulk solution at the intended ratio, and that mixed solution is filled and freeze-dried.

The result is a single porous cake in which the three compounds are distributed together. There is no layering and no separate compartments. When a researcher dissolves it, every aliquot carries the same ratio as the bulk solution did, which is the whole point of buying a glow peptide blend rather than mixing three vials at the bench.

The ratio is fixed at the factory. A blend cannot be re-proportioned afterwards, so a laboratory that wants a different balance of the three needs the single-peptide vials instead. For a fixed-ratio question, the blend removes two weighing steps and two sources of error.

How a certificate of analysis reports a blend

Purity for research peptides is normally measured by reversed-phase HPLC. The review by Mant and colleagues on HPLC of peptides explains the principle: peptides are separated on a hydrophobic column and elute at different times depending on their sequence, and the area under each peak is proportional to the amount of that compound.

For a single peptide, the certificate shows one main peak and a purity percentage, which is the main peak's share of the total area. For a blend, the chromatogram should show three main peaks at three retention times, one for each component, and the certificate should assign a purity figure to each.

Identity is a separate question from purity. A retention time tells the analyst that something eluted when BPC-157 would; mass spectrometry confirms the eluted compound has the expected mass. Huang and colleagues (2015) give BPC-157's relative molecular mass as 1419, and a certificate for a glow peptide vial should show an observed mass for each of the three peptides that matches its expected value.

Three things to check on any blend certificate:

each component is named, with its own retention time and purity
each identity is confirmed by mass, not only by retention time
the total mass in the vial is stated, so the per-component content can be worked out

LynxLab stocks GLOW for research use as a 70mg blend vial at £59.99, with every component tested to 99% purity and the lab report on the product page. The certificate of analysis for each batch is published, and the companion post on why these three peptides are studied together covers the research behind each component.

What the FDA says about impurities in these three peptides

The FDA's category 2 list of bulk drug substances is worth reading for its analytical comments as much as its regulatory ones. For BPC-157 it notes "complexities with regard to peptide-related impurities and active pharmaceutical ingredient characterization". For injectable GHK-Cu it flags "the potential for aggregation and peptide-related impurities". For the thymosin beta-4 fragment LKKTETQ, which is TB-500, it raises immunogenicity for certain routes.

Those are the agency's reasons for keeping the compounds out of US pharmacies. They are also a checklist of what a good certificate should rule out: truncated or deletion sequences from synthesis, oxidised residues, and aggregates that would show as extra peaks or shoulders.

Stability: which residues are fragile

Peptide stability depends on sequence, and the sequences of the three components are known. Sigma-Aldrich's handling guidance lists cysteine, methionine and tryptophan as prone to air oxidation, and asparagine, glutamine, cysteine, methionine and tryptophan as unstable in solution.

BPC-157's sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) contains none of the oxidation-prone residues. TB-500's active sequence LKKTETQ ends in glutamine, one of the residues the guidance flags as unstable once dissolved. GHK is glycyl-histidyl-lysine, and in the copper-bound form the histidine and the metal are the parts most sensitive to pH.

The practical consequence is that a blend is only as stable as its least stable component, and in GLOW that is the TB-500 fraction once it is in solution. In the dry state, all three are far more forgiving.

Storage: what the supplier guidance says

The most consistent advice in the handling literature is to keep peptides dry and cold. Sigma-Aldrich recommends storing lyophilised peptides at -20°C, or -80°C for long periods, away from bright light, and allowing a vial to reach room temperature before opening so that atmospheric moisture does not condense on the powder.

Once dissolved, the same guidance gives peptide solutions about a week at 4°C, recommends sterile buffers at pH 5 to 6, warns against pH above 8, and advises freezing single-use aliquots rather than repeatedly freezing and thawing one tube.

Laboratories that dissolve a blend typically use a bacteriostatic diluent so the vial can be drawn from more than once. Bacteriostatic water is sterile water with 0.9% benzyl alcohol added as a preservative; the US label describes it as a multiple-dose container at pH 5.7 (range 4.5 to 7.0) and states that it must not be used in neonates. The pH sits inside the range Sigma-Aldrich recommends for peptide solutions.

None of this is specific to glow 70mg vials. It is the general handling literature for synthetic peptides, applied to a vial that happens to contain three.

What a buyer should expect from a UK supplier

The research community has no formal standard for how a blend certificate should look, so the buyer has to apply the single-peptide standard three times. Anyone who wants to buy glow for laboratory work should expect to see each component identified by mass, each with its own purity figure, and a stated total content that adds up.

A supplier that reports one purity number for a three-peptide vial has measured the whole cake against its own impurities, which says nothing about whether the three are present in the intended ratio. Any glow uk listing should be judged on that distinction.

Frequently asked questions

How is a peptide blend made in one vial?

The components are dissolved together in a single bulk solution at the intended ratio, filtered, filled into vials and freeze-dried as one batch. The FDA describes freeze-drying as freezing, primary drying by sublimation and secondary drying by desorption. The resulting cake holds all components in a fixed ratio.

How does a lab report show purity for each peptide in a blend?

By reversed-phase HPLC, the three peptides separate into three peaks at different retention times, and each peak's area gives that component's purity. Mass spectrometry confirms the identity of each peak against its expected molecular mass. A certificate that gives only one purity figure for the whole vial has not separated the components.

How should a lyophilised peptide blend be stored?

Supplier guidance from Sigma-Aldrich is to store the dry powder at -20°C or colder, away from light and moisture, and to let the vial warm to room temperature before opening. Peptide solutions are given about a week at 4°C, with single-use aliquots frozen rather than repeatedly thawed.

Is bacteriostatic water the same as sterile water?

No. Bacteriostatic water for injection is sterile water with 0.9% benzyl alcohol added as a preservative, supplied in a multiple-dose container; plain sterile water has no preservative and is intended for single use. The US label for bacteriostatic water states it must not be used in neonates because of benzyl alcohol toxicity.

Sources

Research use only

GLOW from LynxLab

70mg vials from £59.99. ≥99% purity, lab report on the page. Same-day dispatch, UK stock.

Buy GLOW